Ionis Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ionis Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $5 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $4 tied up three years earlier. Less money tied up than 87% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-8.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 51% of Healthcare companies in United States.
Cash Locked Ratio
$5For every $100 of sales, $5 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $4 tied up three years earlier.
Less money tied up than 87% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$31Sales grew 61% in 3 years, but profit fell: $31 less profit per $100 of extra sales.
Lower than 79% of Healthcare companies in United States.
Asset Productivity Ratio
+61% / +39%In 3 years sales changed by +61% while total assets changed by +39%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-0.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 68% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Ionis Pharmaceuticals, Inc. made a loss over the last year. Ionis Pharmaceuticals, Inc. owes $0.85 for every $1 it owns. Ionis Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossIonis Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
16.59The share price is 16.59 times Ionis Pharmaceuticals, Inc.'s book value per share, higher than 92% of Healthcare companies in United States.
Market cap
$7.3 BThe total market value of all of Ionis Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 87% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$440 MWhat Ionis Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.65Net worth divided by the number of shares. The share price of $43.91 is 16.6 times this, which is the P/B above.
Return on equity (ROE)
-105.5%Ionis Pharmaceuticals, Inc. lost 105.5% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
Owes vs Owns
0.85×Ionis Pharmaceuticals, Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Dividend yield
NoneIonis Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+34%Revenue rose 34% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Profit growth
LossIonis Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-40.4%Ionis Pharmaceuticals, Inc. lost $40 for every $100 of revenue.
Interest cover
Not coveredIonis Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashIonis Pharmaceuticals, Inc. held $613 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ionis Pharmaceuticals, Inc.: $7.3 B ÷ $440 M (30 Jun 2026) = 16.6.
What is Ionis Pharmaceuticals, Inc.'s return on equity?
Ionis Pharmaceuticals, Inc. lost 105.5% of its shareholders' money over the last year, lower than 72% of Healthcare companies in United States.
How much does Ionis Pharmaceuticals, Inc. owe compared with what it owns?
Ionis Pharmaceuticals, Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Does Ionis Pharmaceuticals, Inc. pay a dividend?
No. Ionis Pharmaceuticals, Inc. does not currently pay a dividend.
Is Ionis Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 34% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.